WPW
TEVA icon

Waldron Private Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Waldron Private Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,957
Closed -$247K – 130
2015
Q1 		$247K Sell
3,957
-1,191
-23% -$69.2K 0.1% 94
2014
Q4 		$296K Sell
5,148
-40
-0.8% -$2.23K 0.12% 72
2014
Q3 		$278K Sell
5,188
-822
-14% -$43.5K 0.13% 68
2014
Q2 		$315K Sell
6,010
-222
-4% -$11.3K 0.15% 70
2014
Q1 		$329K Buy
6,232
+409
+7% +$18.9K 0.16% 62
2013
Q4 		$233K Buy
+5,823
New +$229K 0.11% 94

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Waldron Private Wealth's TEVA Position: Q2 2015 in Review

Waldron Private Wealth sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 3,957 shares — an estimated $247K sold.

Waldron Private Wealth first reported a position in TEVA in Q4 2013 and held it in 6 quarters. The position peaked at $329K in Q1 2014. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • Waldron Private Wealth reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Waldron Private Wealth sold 3,957 Teva Pharmaceuticals shares in Q2 2015, an estimated $247K.
  • Waldron Private Wealth first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Waldron Private Wealth's Teva Pharmaceuticals position peaked at $329K in Q1 2014.
  • 818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Waldron Private Wealth's 13F filing for Q2 2015, filed 12 Aug 2015.